{"DataElement":{"publicId":"6588337","version":"1","preferredName":"Distal Bile Duct Cancer AJCC Edition 8 Group Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories and relevant prognostic factors for distal bile duct carcinoma, using AJCC Ed. 8 criteria.","longName":"DBD_AJC8_DZ_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6587451","version":"1","preferredName":"Distal Common Bile Duct Neoplasm Pathologic Stage Grouping","preferredDefinition":"The section of the tube-like structure carrying bile that is closest to the intestine and furthest from the hepatic and cystic ducts._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Caused by or altered by or manifesting disease or pathology._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"6587437v1.0:2230144v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"6587437","version":"1","preferredName":"Distal Common Bile Duct Neoplasm","preferredDefinition":"The section of the tube-like structure carrying bile that is closest to the intestine and furthest from the hepatic and cystic ducts.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C60801:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Distal Common Bile Duct","conceptCode":"C60801","definition":"The section of the tube-like structure carrying bile that is closest to the intestine and furthest from the hepatic and cystic ducts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD2B5BC-6CC9-06E4-E053-F662850A2B94","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230144","version":"1","preferredName":"Pathologic Stage Grouping","preferredDefinition":"Pathologic; caused by or altered by or manifesting disease or pathology.:Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C25610:C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CCE-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"7CD295D1-E8FC-06EC-E053-F662850A3CC8","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8-30-19 tmt released.; 12/12/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6587694","version":"1","preferredName":"Distal Bile Duct Carcinoma American Joint Committee on Cancer Edition 8 Group Stage","preferredDefinition":"A term that refers to the staging of distal bile duct cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to bile duct adenocarcinomas, biliary intraepithelial neoplasia, high-grade neuroendocrine carcinomas, and papillary carcinomas. Tumors arising in the ampulla of Vater, sarcomas, and well-differentiated neuroendocrine tumors (carcinoids) are not staged using this staging system. (from AJCC 8th Ed.)_An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6587694v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IV","valueDescription":"Stage IV Distal Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587696","version":"1","preferredName":"Stage IV Distal Bile Duct Cancer AJCC v8","longName":"6587696","preferredDefinition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IV Distal Bile Duct Cancer AJCC v8","conceptCode":"C134820","definition":"Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD635D9-9305-595C-E053-F662850A235A","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD635D9-931E-595C-E053-F662850A235A","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Distal Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587698","version":"1","preferredName":"Stage IIIB Distal Bile Duct Cancer AJCC v8","longName":"6587698","preferredDefinition":"Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Distal Bile Duct Cancer AJCC v8","conceptCode":"C134819","definition":"Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD635D9-932B-595C-E053-F662850A235A","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD635D9-9344-595C-E053-F662850A235A","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"IIB","valueDescription":"Stage IIB Distal Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587700","version":"1","preferredName":"Stage IIB Distal Bile Duct Cancer AJCC v8","longName":"6587700","preferredDefinition":"Stage IIB includes: (T2, N1, M0); (T3, N0, M0); (T3, N1, M0). T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIB Distal Bile Duct Cancer AJCC v8","conceptCode":"C134816","definition":"Stage IIB includes: (T2, N1, M0); (T3, N0, M0); (T3, N1, M0). T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD635D9-9351-595C-E053-F662850A235A","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD635D9-936A-595C-E053-F662850A235A","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Distal Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587702","version":"1","preferredName":"Stage IIIA Distal Bile Duct Cancer AJCC v8","longName":"6587702","preferredDefinition":"Stage IIIA includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Distal Bile Duct Cancer AJCC v8","conceptCode":"C134818","definition":"Stage IIIA includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD635D9-9377-595C-E053-F662850A235A","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD635D9-9390-595C-E053-F662850A235A","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"IIA","valueDescription":"Stage IIA Distal Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587704","version":"1","preferredName":"Stage IIA Distal Bile Duct Cancer AJCC v8","longName":"6587704","preferredDefinition":"Stage IIA includes: (T1, N1, M0); (T2, N0, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIA Distal Bile Duct Cancer AJCC v8","conceptCode":"C134815","definition":"Stage IIA includes: (T1, N1, M0); (T2, N0, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD635D9-939D-595C-E053-F662850A235A","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD635D9-93B6-595C-E053-F662850A235A","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Distal Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587706","version":"1","preferredName":"Stage I Distal Bile Duct Cancer AJCC v8","longName":"6587706","preferredDefinition":"Stage I includes: T1, N0, M0. T1: Tumor invading the bile duct wall with a depth less than 5 mm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Distal Bile Duct Cancer AJCC v8","conceptCode":"C134813","definition":"Stage I includes: T1, N0, M0. T1: Tumor invading the bile duct wall with a depth less than 5 mm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD635D9-93C3-595C-E053-F662850A235A","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD635D9-93DC-595C-E053-F662850A235A","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"},{"value":"0","valueDescription":"Stage 0 Distal Bile Duct Cancer AJCC v8","ValueMeaning":{"publicId":"6587708","version":"1","preferredName":"Stage 0 Distal Bile Duct Cancer AJCC v8","longName":"6587708","preferredDefinition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ/high-grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Distal Bile Duct Cancer AJCC v8","conceptCode":"C134812","definition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ/high-grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD635D9-93E9-595C-E053-F662850A235A","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CD635D9-9402-595C-E053-F662850A235A","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6587693","version":"1","preferredName":"Distal Bile Duct Cancer by AJCC v8 Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the staging of distal bile duct cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to bile duct adenocarcinomas, biliary intraepithelial neoplasia, high-grade neuroendocrine carcinomas, and papillary carcinomas. Tumors arising in the ampulla of Vater, sarcomas, and well-differentiated neuroendocrine tumors (carcinoids) are not staged using this staging system. (from AJCC 8th Ed.):An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C134811:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Distal Bile Duct Cancer by AJCC v8 Stage","conceptCode":"C134811","definition":"A term that refers to the staging of distal bile duct cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to bile duct adenocarcinomas, biliary intraepithelial neoplasia, high-grade neuroendocrine carcinomas, and papillary carcinomas that arise from the distal bile duct. Tumors arising in the ampulla of Vater, sarcomas, and well-differentiated neuroendocrine tumors (carcinoids) are not staged using this staging system. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CD635D9-92D8-595C-E053-F662850A235A","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"ONEDATA","dateModified":"2018-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7CD635D9-92E9-595C-E053-F662850A235A","latestVersionIndicator":"Yes","beginDate":"2018-12-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-12","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8-20-19 released per MC.; 12/12/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"6581918","version":"1","longName":"Bile Duct(s)","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Disease stage","type":"Preferred Question Text","description":"Disease stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7CE6AFB9-8562-7D3B-E053-F662850A29B5","latestVersionIndicator":"Yes","beginDate":"2018-12-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-13","modifiedBy":"KNABLEJ","dateModified":"2020-02-24","changeDescription":"2/24/20 jk removed CPTAC CSI.  8-30-19 TMT released per MC.; 12/13/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}